Anti-Human IL-17RA/IL-17R Reference Antibody (Lusvertikimab, RUO)

Description: Lusvertikimab (BS10718) is a research-grade recombinant antibody targeting CD127. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: IgG4-Kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: IL7R,Interleukin-7receptorsubunitalpha,IL-7R-alpha,IL-7receptorsubunitalpha,CD127,CDw127,IL-7Rsubunitalpha,IL-7RA
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: Effi-7,Effi7-h,MD-707,CAS:2375835-91-7
Background: Interleukin-7 receptor subunit alpha (CD127/IL7R) is a ~51 kDa protein. Receptor for interleukin-7. Also acts as a receptor for thymic stromal lymphopoietin (TSLP).
Note: For research use only. Not suitable for clinical or therapeutic use.